Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 70518-0122

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-0122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Duloxetine Delayed-Release 60 mg capsules, containing 90 capsules per bottle. The label indicates the product is for prescription use only (RX ONLY) and is repackaged by RemedyRepack Inc. Directions refer to the package insert, with storage conditions noted. The manufacturer is Breckenridge, Boca Raton, FL.*

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride, showing its molecular arrangement including aromatic rings, sulfur-containing thiophene, and amine hydrochloride components.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph showing the proportion of patients with relapse over time in days from randomization. It compares two treatments: placebo (dashed line) and duloxetine delayed-release capsules (solid line), indicating a lower relapse proportion for duloxetine over a period of approximately 200 days.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier curve showing the proportion of patients with relapse over time in days. It compares placebo treatment (dashed line) with duloxetine delayed-release capsules (solid line), illustrating a lower relapse rate over time for the duloxetine group.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph showing the percentage of patients improved against percent improvement in pain from baseline. It compares four groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg QD, and Placebo, illustrating patient response levels across these treatments.*

FDA Label Image

Figure 4 (Duloxetine 05)

Line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo, showing trends across varying levels of pain improvement.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares the effects of Duloxetine 60 mg taken twice daily, once daily, and placebo over a range of pain improvement percentages.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine Delayed-Release dosages of 120 mg, 60 mg, and 20 mg once daily with placebo over a range of pain improvement percentages.*

FDA Label Image

Figure 7 (Duloxetine 08)

A line graph showing the percentage of patients improved plotted against the percent improvement in pain from baseline. The graph compares two groups: patients receiving 60 mg duloxetine once daily and those receiving placebo, illustrating the relationship between pain improvement and treatment over a range of improvement percentages.*

FDA Label Image

Figure 8 (Duloxetine 09)

A line graph comparing the percentage of patients improved over various percent improvements in pain from baseline (BOCF). The graph shows two treatments: Placebo and Duloxetine Delayed-Release 60 mg/120 mg once daily, plotted as lines with marked data points representing patient improvement percentages.*

FDA Label Image

Figure 9 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline using the BOCF method. It shows two lines representing placebo and Duloxetine Hydrochloride 60 mg once daily, tracking patient response decline as pain improvement percentage increases.*

FDA Label Image

Figure 10 (Duloxetine 11)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. Two lines compare placebo and Duloxetine (60/120 mg once daily) treatments, illustrating greater patient improvement with Duloxetine across the pain improvement spectrum.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.